Home » Stocks » Translate Bio

Translate Bio, Inc. (TBIO)

Stock Price: $17.86 USD 0.41 (2.35%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.17B
Revenue (ttm) 10.98M
Net Income (ttm) -94.38M
Shares Out 62.91M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $17.86
Previous Close $17.45
Change ($) 0.41
Change (%) 2.35%
Day's Open 17.50
Day's Range 17.23 - 18.66
Day's Volume 2,642,311
52-Week Range 6.80 - 28.09

More Stats

Market Cap 1.17B
Enterprise Value 1.03B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 62.91M
Float 29.56M
EPS (basic) -1.73
EPS (diluted) -1.71
FCF / Share -1.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.85M
Short Ratio 2.62
Short % of Float 7.74%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 106.86
PB Ratio 10.53
Revenue 10.98M
Operating Income -96.36M
Net Income -94.38M
Free Cash Flow -96.90M
Net Cash 143.54M
Net Cash / Share 2.18
Gross Margin -353.97%
Operating Margin -877.24%
Profit Margin -859.20%
FCF Margin -882.20%
ROA -21.21%
ROE -79.38%
ROIC -92.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(69.60% upside)
Current: 17.86
Target: 30.29
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth449.58%---
Gross Profit7.801.42--
Operating Income-116-104-79.25-26.80
Net Income-113-97.40-66.44-26.70
Shares Outstanding51.4526.957.761.51
Earnings Per Share-2.20-3.64-8.66-18.14
Operating Cash Flow-82.16-22.13-50.79-23.72
Capital Expenditures-3.54-6.58-2.77-0.86
Free Cash Flow-85.70-28.71-53.56-24.58
Cash & Equivalents19014560.0271.75
Total Debt12.61---
Net Cash / Debt17714560.0271.75
Book Value154125-93.52-38.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Translate Bio, Inc.
Country United States
Employees 93
CEO Ronald C. Renaud

Stock Information

Ticker Symbol TBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TBIO
IPO Date June 28, 2018


Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious diseRaNA Therapeutics, LLCase pathogens, as well as against COVID-19. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.